196 related articles for article (PubMed ID: 30322329)
1. Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.
Zinzani PL; Santoro A; Chiti A; Lastoria S; Pinto A; Rigacci L; Barosi G; Pennisi M; Corradini P
Leuk Lymphoma; 2019 May; 60(5):1204-1213. PubMed ID: 30322329
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
3. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
4. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Herbaux C; Merryman R; Devine S; Armand P; Houot R; Morschhauser F; Haverkos B
Blood; 2018 Jul; 132(1):9-16. PubMed ID: 29720488
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
Casadei B; Broccoli A; Stefoni V; Pellegrini C; Marangon M; Morigi A; Nanni L; Lolli G; Carella M; Argnani L; Cavo M; Zinzani PL
Haematologica; 2019 Nov; 104(11):e521-e522. PubMed ID: 30890595
[No Abstract] [Full Text] [Related]
7. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
10. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma.
Epperla N; Herrera AF
Blood; 2021 Aug; 138(7):520-530. PubMed ID: 33889927
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.
Dercle L; Ammari S; Seban RD; Schwartz LH; Houot R; Labaied N; Mokrane FZ; Lazarovici J; Danu A; Marabelle A; Ribrag V; Michot JM
Eur J Cancer; 2018 Mar; 91():136-144. PubMed ID: 29360605
[TBL] [Abstract][Full Text] [Related]
12. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
13. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
14. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.
Allen PB; Winter JN
Curr Oncol Rep; 2019 Mar; 21(5):39. PubMed ID: 30919161
[TBL] [Abstract][Full Text] [Related]
15. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
16. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
18. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
20. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
Wang Y; Nowakowski GS; Wang ML; Ansell SM
J Hematol Oncol; 2018 Apr; 11(1):57. PubMed ID: 29685160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
